Recall: Atovaquone
Apr. 2023Pharmacy Updates
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension, USP 750 mg/5 mL, lot #E220182 with an expiration date of 12/2023, due to possible bacterial contamination in the product. This drug is used for the prevention and treatment of a lung infection called Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years old and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. Read the full text of the Atovaquone recall.
Recent Announcements
Important updates on influenza prevention and treatment
As we continue to navigate flu season, we want to emphasize three critical areas to ensure the health and safety of your patients who are UPMC Health Plan members: Consider antiviral therapy when appropriate, encourage masking to prevent the spread of respiratory viruses, and continue to recommend the flu vaccine.Feb. 2025Important Notices
Provider OnLine Enhancements
Provider OnLine will soon be launching enhancements to the authorization process.Feb. 2025Important Notices
CME Webinar: Asthma Clinical Guideline Updates
Please join us for a live, CME-accredited webinar on Wednesday, April 30, that will provide an overview of asthma clinical guideline updates.Feb. 2025Education/Webinars